Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance.
about
Mechanisms by which diabetes increases cardiovascular disease.Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes.Activation of protein kinase C isoforms and its impact on diabetic complications.Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide.Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction.Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress.Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitusDisruption of the murine protein kinase Cbeta gene promotes gallstone formation and alters biliary lipid and hepatic cholesterol metabolismProtein kinase Cβ deficiency attenuates obesity syndrome of ob/ob mice by promoting white adipose tissue remodeling.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyDiabetes-related alterations in the enteric nervous system and its microenvironment.Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus.PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts.Cellular mechanisms and signalling pathways activated by high glucose and AGE-albumin in the aortic endothelium.Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instabilityChronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.Regulation of Vascular Smooth Muscle Cell Dysfunction Under Diabetic Conditions by miR-504Atherosclerosis in diabetes and insulin resistance.A cardiologist view of vascular disease in diabetes.Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.L-Arginine prevents metabolic effects of high glucose in diabetic mice.Loss of protein kinase Cbeta function protects mice against diet-induced obesity and development of hepatic steatosis and insulin resistance.Vimentin is a target of PKCβ phosphorylation in MCP-1-activated primary human monocytes.Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes.Catalpol ameliorates diabetic atherosclerosis in diabetic rabbits.Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal functionNitric oxide differentially affects ERK and Akt in type 1 and type 2 diabetic rats.New insights into insulin action and resistance in the vasculature.Clinical science review article: understanding the implications of diabetes on the vascular system.Exercise and type 1 diabetes (T1DM).Metabolic syndrome in pediatric cancer survivors: a mechanistic review.Cellular and molecular mechanisms of endothelial dysfunction in diabetes.NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links.Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice.Cellular cholesterol regulates monocyte deformation.Pathophysiology of peripheral arterial disease in diabetes mellitus.
P2860
Q30441275-E55E955C-214A-44CD-98EA-B5011BCBB9C2Q33536636-923D1FA7-6FE1-4E9A-BB4B-F483C3CEFDD0Q33881442-B005DB12-5A63-4697-BD5E-20CDA942E30DQ33901576-0FF96AD2-DFB9-4986-9F4C-DD9317244053Q34269858-AB96D58C-5D1C-4DCA-BD64-7017478B0873Q34537384-5ABC44E1-9B5C-4E28-98AE-CB2EFD3F54F1Q34605273-1BD9AFA9-0BC7-4E13-9C5C-B43BBECE2340Q34931190-366E7D48-A43D-4D9F-88CF-9FBA65D4318BQ35067675-5F7EC46B-08F0-4FF8-A0F8-974AB18D2979Q35747746-1DA0ABF5-1D8C-468C-B332-F31936E2B8D9Q35755253-FFE52401-D830-43F6-A01C-94DD87BADFCFQ35988135-E5668320-2946-4F6C-A61B-0B843DECE4A8Q36250613-8330F2A8-B3D9-4119-A28D-7F516917B457Q36384149-4137DF74-95E0-4BC7-B23E-60B88B1CDF22Q36610687-06BA756E-4D4F-4B2D-954B-9CA50C794003Q36618518-45EA68A6-308B-4ED3-A761-99511DC837F5Q36687957-47CB7E83-6B82-48F4-833C-0D0E642BD941Q36741853-777D5E13-60B4-4B7E-B9BB-80FC75692F68Q36776710-C9B870EA-6F19-4A43-B7BD-3E8C0380EE81Q36849525-D906446E-6F82-4C54-BD4E-883D86465831Q36857541-D3296E67-8936-4FD2-A57E-927447F74186Q36973815-672B57BF-B4DF-41AE-AD15-E5D47FA603D2Q37172727-E3E0BCAD-14BA-47DE-9454-0463108327E5Q37258326-F802AC8E-9C5C-453E-8119-729F58451867Q37308701-D4D14173-13B1-4FCF-8706-56ED147BF8D3Q37319302-736691F6-BEB0-41D4-B7CC-420CDEA3EC1FQ37387934-7B16646D-1BF9-4434-A79B-B30183099FDEQ37393435-230D5545-5467-4DA0-8101-5264324DDEB0Q37567611-7D9320D8-0804-4A17-944F-9B0D1FF60FB1Q37619165-920901D9-656C-4389-BF0D-163EF8AA9CA6Q37661426-E0CD2581-C3C6-40CE-AB8B-365F1B201361Q37707789-B9530FED-64A1-4ED9-9C07-1D83ADD4B127Q37875591-923F9C02-63B5-4237-AB8E-309B17397A2CQ38125149-DF99A448-9B2D-412A-B1D6-937271013DC0Q38126459-9919F992-E6E6-4C3B-AFDF-1888C4AE33CEQ38134022-7C40A769-9DF3-4C80-8146-2DF00F7AAA44Q38227386-AC89CC78-A6EC-4987-BB65-973283D66277Q38335202-B45B8D88-ECE3-429F-876F-2FB57B6968CBQ38721601-291C2D7C-1646-489A-9B6F-91498CEE7B05Q38936026-A13D1A52-8659-4A0F-9890-3C10B5B9721E
P2860
Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@ast
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@en
type
label
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@ast
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@en
prefLabel
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@ast
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@en
P1476
Proatherosclerotic mechanisms ...... abetes and insulin resistance.
@en
P2093
Christian Rask-Madsen
George L King
P304
P356
10.1161/01.ATV.0000155325.41507.E0
P407
P577
2005-01-06T00:00:00Z